Nuformix PLC (LSE:NFX) said it filed a second patent application for a new family of co-crystalline forms of a drug already on the market that had sales of more than £1bn in 2020.
The application covers the company’s NXP004 re-formulation of the unnamed product.
Chief executive Anne Brindley said: “Data that we have generated on these new co-crystal forms in the past six months has shown improvements over the marketed form that justifies filing this new application.
“This application, if granted, will strengthen the patent estate for NXP004 and Nuformix's IP portfolio as a whole."
The company specialises in repurposing or improving existing treatments.